{"id":"W4322422773","doi":"10.1016/s1470-2045(23)00049-9","title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Everolimus; Internal medicine; Oncology; Clinical endpoint; Kidney cancer; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004562708,0.0004559883,0.001541661,0.00008732713,0.0003106698,0.00002954114,0.0006420188,0.0001176311,0.0002442506],"category_scores_gemma":[0.0001567325,0.0002278595,0.0001388856,0.0004682135,0.0002465836,0.0000808019,0.0002510395,0.0002653673,0.0001216512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000656269,"about_ca_system_score_gemma":0.000547237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001298153,"about_ca_topic_score_gemma":0.001187276,"domain_scores_codex":[0.9969317,0.0006704592,0.0006291459,0.0006016468,0.0005391449,0.000627909],"domain_scores_gemma":[0.9956392,0.00214718,0.0004747391,0.001334969,0.0002324024,0.0001715084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9295806,0.01507069,0.0102689,0.00004315742,0.001302208,0.0009142812,0.009230685,0.0001076132,0.0006329783,0.00003427197,0.001863954,0.03095071],"study_design_scores_gemma":[0.8163802,0.09713788,0.0727483,0.00003885209,0.001585944,0.00001217373,0.002308475,0.0001560159,0.003036389,0.00005137736,0.006305909,0.000238491],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857422,0.0002954958,0.000004625198,0.00176262,0.0004467183,0.00650448,0.0002690068,0.00008482509,0.004890015],"genre_scores_gemma":[0.9959043,0.0001907613,0.0001934891,0.0002401399,0.0003430797,0.001010613,0.0007510589,0.00007379396,0.001292786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1132003,"threshold_uncertainty_score":0.9291839,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180846668618132,"score_gpt":0.3742417348262079,"score_spread":0.2561570679643946,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}